IMP.VN
Unloved QualityImexpharm Corporation · Healthcare · Vietnam · $214M cap · $7K/day traded
VND 35,700 +0.0% · close 6 Nov · scored 7 Nov
Score up 1.1 since 6 Nov.
Unloved Quality: Strong and cheap, but the market has not warmed to it.
As of 7 Nov 2026, the MoatMap Score for Imexpharm Corporation (IMP.VN) is 81/100, ranked against 25,000+ stocks in 38 markets (Quality 76, Value 60, Momentum 43, each scored against its sector).
Does the score work? Each tenth of the ranking, tracked monthly. See the record →
ABOUT IMEXPHARM CORPORATION
Read
Imexpharm Corporation operates as a pharmaceutical company in Vietnam. The company's products include injectable antibiotics, oral antibiotics, cardiovascular, ophthalmology, musculoskeletal system, analgesic - anti-inflammatory - antipyretics, respiratory system, antihistamines and anti-allergy,...
FINANCIAL SUMMARY (VND)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.6T | 2.0T | 2.2T | 2.4T | 14.1% | 2.3T | 2.7T | 2.9T | 8.6% |
| EPS (VND) | 1,194 | 1,804 | 1,932 | 1,976 | 18.3% | 1,468 | 2,304 | 2,499 | 12.5% |
| Shares | 154.0M | 154.0M | 154.0M | 154.0M | -0.0% | 154.0M | — | — | — |
| Debt | 95.0B | 49.4B | 86.1B | 212.8B | 30.8% | 210.8B | — | — | — |
| Equity | 1.9T | 2.1T | 2.2T | 2.3T | 6.8% | — | — | — | — |
| Op CF | 378.6B | -39.5B | 216.3B | 54.2B | -47.7% | 386.9B | — | — | — |
| Inv CF | -199.3B | 79.1B | -127.2B | -76.6B | — | — | — | — | — |
| Fin CF | -271.7B | -112.2B | -33.3B | 49.7B | — | — | — | — | — |
No new 52-week low for 14 weeks, 9% above that low, but not back above a rising 50-day average.
Calmer than 85% of stocks we rank over the past year (volatility 24% a year).
How this is worked out
The MoatMap Score weighs the business, its price and its trend. The price check reads only the chart: the price side of the Momentum score, in words.
The rules: Still falling is a new 52-week low in the last two weeks, at least 25% below the high. Finding a floor is no new low since. Turning up is 20 or more trading days without a new low, at least 10% off it, and back above a rising 50-day average. In an uptrend is above the 200-day average and within 15% of the high.
In 2,112 US drawdowns since 2001, buying while the price was still falling was followed by a further 20% drop 42% of the time. Waiting for a turn (the Turning up rule above) cut that to 33%, at about 7% higher prices and with no better returns. Part of that cut is simply not buying: 13% of falls never turned, and waiting kept those out. Among turns that were bought, 38% still fell another 20%, and 33% of turns were followed by a new low within six months. The benefit was largest in crashes such as 2008 and 2020.
What it measures: how much the price moved day to day over the past year, scaled to a yearly figure (annualised volatility) and ranked against every stock we cover. Very calm under 20% a year, Calm 20 to 30%, Average 30 to 40%, Bumpy 40 to 55%, Very bumpy above that.
What we found: across about 13,500 stocks in 34 markets (2002 to 2025), past swings were a good guide to the next year's, and bumpier stocks fell further. How much further changed too much between eras to put a number on it.
Calm is not safe: a calm stock can still slide steadily.
Rules fixed before any data was fetched. Describes the chart, not a recommendation.
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of IMP.VN are excluded.
Peer medians: ROE 17.8% · P/E 13.0x · Gross margin 45.7%
Company Deep Dive
A 10,000-word report: the business and its segments, what management promised on earnings calls and whether it delivered, the competition, and how things could turn out.